Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorEwha Womans University Mokdong Hospital
About this trial
The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.
Eligibility criteria
Qualifiers
Participants must be 19 years of age or older at the time of informed consent.
Patients who are undergoing medical evaluation for newly approved Alzheimer's disease medications after 2021, patients who have decided to initiate treatment with these medications in consultation with their physician after 2021, or patients who have already started treatment with newly approved Alzheimer's disease medications after 2021.
Patients who have undergone an amyloid PET scan to confirm Alzheimer's disease pathology, or cerebrospinal fluid testing for Aβ42 and ptau181.
[Alzheimer's Disease Dementia (ADD)] - Must meet the criteria for probable Alzheimer's dementia as defined by the National Institute on Aging and the Alzheimer's Association working groups (NIA-AA).
Disqualifiers
Presence of significant psychiatric disorders associated with intellectual disability, schizophrenia, major depression, bipolar disorder, delirium, etc.
History of substance abuse or alcohol dependence that required treatment within the past five years.
A current diagnosis of cancer that has not achieved remission within the past five years. However, localized prostate cancer, cervical carcinoma in situ, non-melanoma skin basal cell carcinoma, or squamous cell carcinoma are excluded.
Evidence of severe or unstable physical conditions (e.g., dialysis, severe liver disease).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
4,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Ewha Womans University Mokdong Hospital
Lead sponsor
Korean Dementia Association
Collaborator
Inha University Hospital
Collaborator
Gachon University Gil Medical Center
Collaborator
Saint Vincent's Hospital, Korea
Collaborator
Gangnam Severance Hospital
Collaborator
Konkuk University Hospital
Collaborator
Kyunghee University Medical Center
Collaborator
Korea University Medicine
Collaborator
Busan University Medical Center
Collaborator
CHA University
Collaborator
Samsung Medical Center
Collaborator
Seoul National University Hospital
Collaborator
Seoul National University Bundang Hospital
Collaborator
Asan Medical Center
Collaborator
Soonchunhyang University Hospital
Collaborator
Ajou University Hospital, Suwon, South Korea
Collaborator
Yonsei University Yongin Severance Hospital
Collaborator
Wonkwang University Hospital
Collaborator
Ewha Womans University Seoul Hospital
Collaborator
InjeUniversityBusanPaikHospital
Collaborator
Chonnam National University Hospital
Collaborator
Jeju National University Hospital
Collaborator
Chungnam National University Hospital
Collaborator
Gyungbook national university hospital
Collaborator
Hanllym University Medical Center
Collaborator
Heavenly Clinical Research
Collaborator
KangWon National University Hospital
Collaborator
Seoul St. Mary's Hospital, The Catholic University
Collaborator
Source ClinicalTrials.gov